Prelude Therapeutics (PRLD)
0.71
-0.08 (-9.81%)
At close: Apr 03, 2025, 2:58 PM
-9.81% (1D)
| Bid | 0.71 |
| Market Cap | 39.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.68 |
| PE Ratio (ttm) | -0.43 |
| Forward PE | -0.76 |
| Analyst | Buy |
| Ask | 0.72 |
| Volume | 90,101 |
| Avg. Volume (20D) | 234,926 |
| Open | 0.74 |
| Previous Close | 0.79 |
| Day's Range | 0.71 - 0.76 |
| 52-Week Range | 0.63 - 6.80 |
| Beta | 1.42 |
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selecti...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 131
Stock Exchange NASDAQ
Ticker Symbol PRLD
Website https://www.preludetx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for PRLD stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 459.44% from the latest price.
Stock Forecasts